USPlabs Jack3d™ Peer-Reviewed Clinical Safety Study Published

10-week Study Confirms Prior Research on DMAA Safety

DALLAS, Feb. 24, 2012 /PRNewswire-USNewswire/ -- USPlabs, maker of the popular Jack3d™ and OxyElite Pro® nutritional supplements, today announced the release of a new study published by the Journal of Nutrition and Metabolic Insights about the safety of USPlabs Jack3d™ when used as directed over a 10-week period.

The study evaluated 25 healthy men, who, over the course of 10 weeks consumed either a placebo or a dietary supplement containing caffeine, 1,3-dimethylamylamine and other dietary ingredients on days they performed regular physical exercise. The results of the study found that USPlabs Jack3d™ did not result in a statistically significant change in resting heart rate, blood pressure or any indicators of liver and kidney function. The supplement was also well-tolerated with no reports of any adverse effects.

The findings of today's study are consistent with previous 2-week and 8-week studies which found no significant increase in blood pressure or liver and kidney function following chronic use of DMAA & DMAA-containing supplements.

The study on the safety of USPlabs Jack3d™ is available online at http://www.la-press.com/impact-of-a-dietary-supplement-containing-13-dimethylamylamine-on-bloo-article-a3040.

USPlabs Jack3d™ and OxyElite Pro® are among the most studied finished dietary supplements ever sold. This most recent study is the 7th peer-reviewed, published clinical trial supporting the safe use of DMAA when used as directed, in addition to an industry estimated over one billion servings consumed by satisfied customers. More specifically, Jack3d™ & OxyElite Pro® have 5 clinical trials that show they are safe when used as directed.

SOURCE USPlabs

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED